Repair of CRISPR-guided RNA breaks enables site-specific RNA editing in human cells.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
29 Aug 2023
29 Aug 2023
Historique:
pubmed:
11
9
2023
medline:
11
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Genome editing with CRISPR RNA-guided endonucleases generates DNA breaks that are resolved by cellular DNA repair machinery. However, analogous methods to manipulate RNA remain unavailable. Here, we show that site-specific RNA breaks generated with RNA-targeting CRISPR complexes are repaired in human cells, and this repair can be used for programmable deletions in human transcripts that restore gene function. Collectively, this work establishes a technology for precise RNA manipulation with potential therapeutic applications.
Identifiants
pubmed: 37693568
doi: 10.1101/2023.08.29.555404
pmc: PMC10491232
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : K99 AI171893
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM134867
Pays : United States
Déclaration de conflit d'intérêts
Competing interests: B.W. is the founder of SurGene LLC and VIRIS Detection Systems Inc. B.W., A. Nemudryi, and A. Nemudraia are inventors of the patent applications US 63/523,592 and US 63/534,305 pertaining to use type III CRISPR-Cas system for sequence-specific editing of RNA filed by Montana State University.